European Health Data & Evidence Network
(Temporary website)

Today, in Europe, we are challenged to generate insights and evidence from real world clinical data at scale, to support patients, clinicians, payers, regulators, governments, and the pharmaceutical industry in understanding wellbeing, disease, treatments, outcomes and new therapeutics and devices. Unfortunately, such data is difficult to use at scale, in a myriad of languages, systems and structures, with challenging policy restrictions and technology considerations. Consequently, using real world data for research, reflective of what happens for patients in their own experience of healthcare, is very challenging.

The Electronic Health Data in a European Network (EHDEN) consortium will provide the infrastructure and eco-system to make this ambition come true.

The main objectives of the EHDEN Consortium are:

  1. To implement a federated health data network in Europe.
  2. To enhance the supply and demand side to form a health data eco-system in compliance with robust privacy and ethics governance.
  3. To enable the development of new and augmented health services through available and expanded technologies, in the interest of improving health outcomes.

Central to EHDEN will be the standardisation of health data to the OMOP common data model and the adoption of analytical tools developed by the international Observational Health Data Sciences and Informatics (OHDSI) open science collaboration ( A network of SMEs will be trained and certified to ensure high validity transformation of data to the common data model.

EHDEN’s aspirations are significant, aiming to harmonise 100 million, anonymised health records across multiple data sources, who can obtain funding from the EHDEN Harmonisation Fund to obtain support from certified/qualified SMEs through serial open calls. The project will support other IMI2 projects within a wider Big Data for Better Outcomes (BD4BO) programme, other IMI and non-IMI projects, and will collaborate strongly with other key stakeholders in Europe, such as the European Medicines Agency.

IMI2 EHDEN is supported by the Innovative Medicines Initiative Joint Undertaking (IMI-JU) under grant agreement number 806968


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA


Erasmus Universitair Medisch Centrum Rotterdam

Synapse Research Management Partners S.L.

The Chancellor, Masters and Scholars Of The University Of Oxford

United Kingdom
Tartu Ulikool

Universidade De Aveiro

The Hyve Bv

Odysseus Data Services s.r.o.

Czech Republic
Forum Europeen Des Patients

National Institute For Health And Care Excellence

United Kingdom
Stiftelsen WHO Collaborating Centre for International Drug Monitoring

International Consortium for Health Outcome Measurement LTD

United Kingdom
Janssen Pharmaceutica

Pfizer Limited

United Kingdom
AbbVie Inc

Institut de Recherches Internationales Servier


Bayer AG

Eli Lilly

United Kingdom
AstraZeneca AB

Novartis Pharma AG


Celgene Management SARL


Contact Us